Does combination therapy with dexamethasone and osteoprotegerin protect against arthritis-induced bone alterations in antigen-induced arthritis of the rat?
The principle of combining a glucocorticoid together with inhibition of the receptor activator of NF-kappaB ligand (RANKL) may be an effective bone-saving therapy in rheumatoid arthritis.
These results suggest that the NK-1 receptor plays an important role in determining the MAC of isoflurane by inhibition of pain transmission in the spinal cord.